- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03422549
Diaphragmatic Electrical Activity in Preterm Infants on Non-Invasive Ventilation
Diaphragmatic Electrical Activity in Preterm Infants on Non-Invasive High Frequency Oscillatory Ventilation (DEAP-NHFO Study)
Study Overview
Status
Intervention / Treatment
Detailed Description
Continuous Positive Airway Pressure is one of the most researched and accepted methods of delivering NIV to term and preterm infants. Non-invasive high frequency ventilation is a relatively new method of delivering NIV respiratory support in preterm infants. Preliminary studies suggest superiority over CPAP, and NHFOV is being increasingly utilized in clinical practice in an attempt to prevent intubation and minimize ventilation-induced lung injury in preterm infants. However, little is known about its mechanism of action and its effect on respiratory mechanics in the newborn. The objective of this study is to compare the effects of non-invasive ventilation (NIV) delivered by nasal Continuous Positive Airway Pressure (CPAP) versus Non-Invasive High Frequency Ventilation (NHFOV) on respiratory pattern as assessed by the electrical activity of the diaphragm (EAdi) in very low birth weight (VLBW) preterm infants.
The investigators hypothesize that in VLBW preterm infants with relative pulmonary insufficiency, NHFOV will reduce respiratory drive and improve ventilation, subsequently resulting in decreased patient diaphragm energy expenditure. This would be demonstrated by decreased neural respiratory rates and/or decreased peak electrical activity of the diaphragm while breathing on NHFOV compared to CPAP.
Clinicians are seeking alternative methods for providing non-invasive respiratory support to preterm infants. NHFOV is a relatively new modality that is being increasingly utilized in clinical practice but has not been well studied. This study will help the investigators determine how non-invasive high frequency ventilation affects breathing in preterm infants, as compared to the more traditional modality of nasal CPAP. Therefore, clinicians will not only be able to better understand how NHFOV works, but also utilize this information to decide on the most appropriate respiratory support modality for preterm patients
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3N1
- Recruiting
- British Columbia Women's Hospital and Health Centre
-
Contact:
- Jonathan Wong, MD
- Phone Number: 7344 16048752345
- Email: jonathan.wong@cw.bc.ca
-
Contact:
- Email: jonathan.wong@cw.bc.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinically stable preterm infants with birth weights ≤1500g admitted to the neonatal intensive care unit (NICU) at the Children's and Women's Hospital of BC
- On nasal continuous positive airway pressure of 6 to 8 cmH20 support for at least 48 hours, treated with methylxanthines for apnea of prematurity and requiring 21-40% of oxygen.
Exclusion Criteria:
- infants with congenital anomalies of the gastrointestinal tract, phrenic nerve damage, diaphragmatic paralysis, esophageal perforation.
- infants with congenital or acquired neurological deficit (including significant intraventricular hemorrhage >Grade II), neonatal seizure.
- infants with significant congenital heart disease (including symptomatic PDA).
- infants with congenital anomalies of the diaphragm.
- infants with congenital anomalies of the respiratory tracts (e.g. Congenital Cystic Adenomatoid Malformation (CCAM)).
- infants requiring ongoing treatment for sepsis, necrotizing enterocolitis (NEC), antibiotics for lung infections, narcotic analgesics, or gastric motility agents.
- infants on nasal CPAP and requiring more than 40% oxygen
- infants with significant gastric residuals and vomiting.
- infants with facial anomalies.
- infants with pneumothorax or pneumomediastinum.
- infants in the immediate postoperative period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: CPAP
Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants. Intervention: Device: Drager VN500 Ventilator |
This ventilator is capable of providing both CPAP and NHFOV support.
|
|
Active Comparator: NHFOV
Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality has not been well studied to date. Intervention: Device: Drager VN500 Ventilator |
This ventilator is capable of providing both CPAP and NHFOV support.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The difference in the peak electrical activity of the diaphragm between CPAP and NHFOV.
Time Frame: 4 hours
|
Measured by the electrical activity of the diaphragm between respiratory support modes (CPAP and NHFOV).
|
4 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in neural respiratory rate.
Time Frame: 4 hours
|
Measured by the electrical activity of the diaphragm between respiratory support modes (CPAP and NHFOV).
|
4 hours
|
|
Difference in neural inspiratory time.
Time Frame: 4 hours
|
Measured by the electrical activity of the diaphragm between respiratory support modes (CPAP and NHFOV).
|
4 hours
|
|
Difference in diaphragm energy expenditure.
Time Frame: 4 hours
|
Measured by the electrical activity of the diaphragm between respiratory support modes (CPAP and NHFOV).
|
4 hours
|
|
Difference in transcutaneous pCO2 on the different modes of non-invasive ventilation.
Time Frame: 4 hours
|
TpCO2 bedside measurement.
|
4 hours
|
|
Difference in the number of apnea episodes.
Time Frame: 4 hours
|
Clinical monitoring and vitals monitoring at the bedside.
|
4 hours
|
|
Differences in SpO2 histogram classification between modes of ventilation.
Time Frame: 4 hours
|
Electronic vitals monitoring.
|
4 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathan Wong, MD, University of British Columbia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H17-02003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Distress Syndrome, Newborn
-
Xu FalinNanyang Central Hospital; Xinyang Central Hospital; Xinxiang Central Hospital; Zhengzhou... and other collaboratorsEnrolling by invitation
-
Vastra Gotaland RegionGöteborg UniversityNot yet recruitingRespiratory Distress Syndrome in Premature Infant | Respiratory Distress Syndrome of Newborn | Respiratory Distress Syndrome (& [Hyaline Membrane Disease]) | Respiratory Distress Syndrome (RDS) | Respiratory Distress Syndrome (Neonatal)
-
Murdoch Childrens Research InstituteWestern Health, Australia; Royal Women's Hospital, Melbourne, AustraliaRecruitingRespiratory Distress Syndrome, Newborn | Respiratory Distress Syndrome in Premature InfantAustralia
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Dr Anna Lavizzari; Dr Francesca Gaia CiuffiniCompletedNewborn Respiratory Distress SyndromeItaly
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Enrolling by invitationRespiratory Distress Syndrome, NewbornBangladesh
-
Hamad General HospitalRecruitingRespiratory Distress Syndrome, NewbornQatar
-
Third Military Medical UniversityUnknownInfant, Newborn | RDS | Vitamin A | SurfactantChina
-
Dr Cipto Mangunkusumo General HospitalCompletedRespiratory Distress Syndrome, Newborn | Neonatal Respiratory DisordersIndonesia
-
The First Affiliated Hospital with Nanjing Medical...UnknownRespiratory Distress Syndrome of NewbornChina
-
Hackensack Meridian HealthNot yet recruitingRespiratory Distress Syndrome, Newborn | Respiratory Distress Syndrome in Premature InfantUnited States
Clinical Trials on Drager VN500 Ventilator
-
Sunnybrook Health Sciences CentreCompletedRespiratory Distress Syndrome, NewbornCanada
-
Prince of Songkla UniversityTerminatedHigh-Frequency VentilationThailand
-
Mount Sinai Hospital, CanadaUnknownRespiratory FailureCanada
-
Draeger Medical Systems, Inc.UnknownRespiratory Distress Syndrome In Premature InfantsUnited States
-
University of Lausanne HospitalsCompletedRespiratoy Failure Requiring NIV TreatmentSwitzerland
-
Federal University of UberlandiaCompletedCoronary Artery Bypass
-
University of MinnesotaRecruiting
-
Mackay Memorial HospitalWithdrawn
-
Boston Medical CenterTerminatedRespiratory InsufficiencyUnited States
-
Hospital Sao DomingosUnknownVentilator-associated PneumoniaBrazil